BACKGROUND: Well-differentiated (WD) and poorly differentiated (PD) pancreatic neuroendocrine neoplasms are biologically distinct entities with different therapies and prognoses. WD neoplasms with elevated proliferation (Ki-67 > 20%) have been shown to have an overlapping histology with PD neuroendocrine carcinomas. This study compared expert cytomorphologic assessments of differentiation in pancreatic neuroendocrine neoplasms in a multi-institutional study. 
INTRODUCTION
Pancreatic neuroendocrine neoplasms are rare, pathologically diverse tumors with varied clinical behavior. The 2017 World Health Organization (WHO) classification of tumors of the digestive system defines welldifferentiated (WD) pancreatic neuroendocrine tumors (PanNETs) as morphologically resembling nonneoplastic islet cells, whereas poorly differentiated (PD) pancreatic neuroendocrine carcinomas (PanNECs) are uniformly high-grade and exhibit a large cell or small cell morphology (large cell neuroendocrine carcinoma or small cell carcinoma). 1 The distinction between WD and PD tumors is supported by different underlying genetic alterations, treatment responses, and outcomes. [2] [3] [4] Emerging genotypes for WD PanNETs include mutations in death domain-associated protein (DAXX), a thalassemia/mental retardation syndrome X-linked (ATRX), and menin 1 (MEN1), whereas PD PanNECs show more similarity to conventional ductal adenocarcinomas and may exhibit mutations of TP53, retinoblastoma 1 (RB1), and KRAS, among others. 4, 5 Approximately 4% of WD PanNETs have TP53 mutations, but they are more likely to occur in PD neuroendocrine carcinomas. WD PanNETs are often completely asymptomatic and can be followed expectantly for months and sometimes years. In contrast, PD neuroendocrine carcinomas behave aggressively and are managed with cytotoxic chemotherapy. 6 Recent changes in the WHO classification of pancreatic neuroendocrine neoplasms reflect the aforementioned data. 1 The neoplasms are categorized into 4 tiers distinguished by their morphologic features and mitotic rate or Ki-67 proliferation rate: grade 1 (G1) PanNETs, grade 2 (G2) PanNETs, grade 3 (G3) PanNETs, and PanNECs (also G3; see Table 1 for the 2017 WHO classification). Thus, PD PanNECs are uniformly high-grade, whereas WD PanNETs can exhibit a spectrum ranging from lowgrade to high-grade. Prognoses and therapeutic responses are markedly different between G3 WD PanNETs and PanNECs, with better median overall survival for G3 WD PanNETs (52 vs 10 months, respectively) but worse response rates to platinum-based therapy (10% and 37%, respectively). 2 Ki-67 rates > 20% do not strictly correlate with WD neoplasms versus PD neoplasms. 7 Furthermore, histologic assessments of differentiation in G3 neuroendocrine neoplasms can be challenging. 8 In cytologic specimens, the appearances of various diagnostic parameters used to assess differentiation differ from those used in histology, including apoptotic debris, mitoses, nucleoli, and chromatin patterns. On this premise, 3 cytopathologists from different institutions with a subspecialty interest in pancreatic cytopathology assessed G2/G3 neoplasms in an attempt to determine the degree of differentiation with standard morphologic definitions for these entities and no training module. Their responses were compared with each neoplasm's final classification, which was based on ancillary information reflecting the underlying current understanding of the tumor biology, including the tumor genotype, a review of prior material, and the immunophenotype (DAXX, ATRX, and RB protein expression). The cytomorphology was then further reviewed, and the association between various cytologic features was assessed in cases with reviewer agreement and in those with disagreement regarding tumor differentiation.
MATERIALS AND METHODS

Case Selection
With institutional review board approval, pancreatic neuroendocrine neoplasms previously classified as G2 or higher on cytology or histology with the 2010 WHO classification system were identified retrospectively by 1 author (C.S.S.) from the pathology database at Memorial Sloan Kettering Cancer Center. 9 Neoplasms with a cytology specimen from a primary or metastatic neoplasm were included. All patients were evaluated clinically at the study institution. Patient demographics, radiology findings, and follow-up information were available for all patients and were obtained from the electronic medical record.
Morphologic Differentiation and Assessment of Cytology Features
Slides were de-identified immediately after their retrieval from the slide archive (by T.D.D.). Representative areas were circled on up to 3 slides (Diff-Quik stain, ThinPrep, and alcohol-fixed smear or cell block with hematoxylineosin stain) by V.W.S. for a blinded review by 3 experienced cytopathologists (C.S.S., D.C., and M.D.R.) with a subspecialty interest in pancreatic cytopathology. For the majority of the cases, 2 to 3 slides were selected, and they included a Diff-Quik stain for 66 patients (92%), a ThinPrep for 41 patients (57%), a cell block for 29 patients (40%), an alcohol-fixed smear with hematoxylin-eosin The Ki-67 indices were not provided. After grading, the same cytology materials from all cases were assessed independently by a cytopathologist and a cytology fellow (C.S.S. and V.W.S) to collect specific cytologic features. The cases were reviewed without knowledge of the results of the initial review and final classification, and all cases with disagreements regarding the presence or absence of features were re-reviewed by C.S.S. and V.W.S. at a multiheaded scope for consensus. The following cytologic features were assessed: nuclear size variation (uniform, nonuniform, or pleomorphic); nuclear shape (round or ovoid); nuclear contour (smooth or irregular); nuclear angulation; chromatin pattern (fine or coarse); and presence or absence of single prominent nucleoli, a plasmacytoid shape, nuclear tangles, nuclear molding, and necrosis. Apoptosis was evaluated in 10 high-power fields (40 3 objective; Olympus BX43) and graded as present (any) or > 5. Mitoses were assessed in 10 high-power fields (40 3 objective; Olympus BX43) as present (any) or > 5.
Ancillary Studies
Available paraffin-embedded cell blocks and core biopsies were cut into 4-lm sections. The antibodies used included DAXX, ATRX, RB, and Ki-67 (Table 2) . Immunohistochemistry (IHC) for DAXX, ATRX, and Ki-67 was performed on BenchMark XT automated equipment (Ventana Medical Systems, Inc, Tucson, Arizona). IHC for RB was performed on a Leica BOND automated system (Leica Biosystems, Wetzlar, Germany). A complete loss of DAXX, ATRX, and RB protein expression in the presence of positive staining in nonneoplastic cells was regarded as abnormal. Internal positive controls for nuclear markers included background lymphocytes, hepatocytes, or stromal cells.
The Ki-67 proliferation rate was assessed for all cases with available material on a combination of various preparations (core biopsies, cell blocks, and alcohol-fixed cytology smears), as previously described. 10 Because of the lack of adequate material for formal mitotic counting (50 highpower fields are required), the grade was assigned solely on the basis of the Ki-67 index with 2017 WHO criteria. For cases with both cytology and biopsy specimens obtained concurrently, the higher Ki-67 rate was used to assign the grade for that biopsy instance.
Results of targeted sequencing for KRAS, DAXX, ATRX, and RB1 were obtained from the institutional pathology database as reported from previous genetic mutation profiling completed with the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a custom nextgeneration sequencing array of 410 cancer-associated genes.
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Final Classification
After blinded categorization, a complete clinicopathologic review, including a review of prior and concurrent biopsy or resection specimens, molecular profiles, and immunohistochemical stains, was performed to determine a classification based on the current biological understanding of these tumors. 12 The final classification of differentiation was assigned on the basis of the criteria in Table 3 . Feedback was provided to the reviewers for cases in which their original diagnosis conflicted with ancillary support for differentiation, and representative cases were reviewed. Cases failing to meet the criteria for classification were rereviewed for consensus (C.S.S., M.D.R., and D.C.) over a WebEx teleconference (Cisco Systems, Inc, San Jose, California). If a consensus could not be reached about Original Article
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Cancer Cytopathology differentiation (WD vs PD), we called the case unclassified (UNC). If a consensus about the cell type (small vs large) for a PD PanNEC could not be reached, we called it poorly differentiated, not otherwise specified (PD-NOS).
Statistical Analysis
Interobserver agreement was calculated with unweighted multirater Cohen j coefficients with corresponding significance testing. The threshold for the significance of a P value was .05. All analyses were performed with Stata 10.0 (StataCorp, College Station, Texas).
RESULTS
Seventy-two pancreatic neuroendocrine neoplasm cytology cases from 68 patients, obtained by endoscopic ultrasound-guided fine-needle aspiration (FNA) of the pancreas (n 5 11) or computed tomography-guided FNA of a metastatic site (n 5 61), were included. Biopsies had been collected either for the initial diagnosis (n 5 35 [49%]: 24 for a liver metastasis, 10 for the pancreas, and 1 for another metastasis) or for an assessment of disease progression in a patient with a known history (n 5 37 [51%]: 36 for a liver metastasis and 1 for a pancreatic recurrence). Previously performed and clinically reported IHC included positive staining for synaptophysin and/or chromogranin (n 5 71 [99%]) and negative staining for at least 1 marker of acinar differentiation (trypsin or chymotrypsin; n 5 41 [57%]). MSK-IMPACT testing had been previously performed for 24 patients on material from 18 liver core biopsies, 5 pancreatectomies, and 1 cell pellet from liver FNA. Fifteen tumors from the 24 tested patients contained mutations contributing to classification as described in Table 4 . Abbreviations: ATRX, a thalassemia/mental retardation syndrome X-linked; DAXX, death domain-associated protein; G1, grade 1; G2, grade 2; IHC, immunohistochemistry; MEN1, menin 1; RB, retinoblastoma. a This did not include the 2 cases that were agreed to be poorly differentiated but were superseded by ancillary information supporting a well-differentiated status. b Nine cases were re-reviewed for a consensus agreement on the morphology after there was disagreement about differentiation when the cases were reviewed independently.
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January 2018 determined with our methods in 2 cases. A summary of the supporting criteria for classification is shown in Table 4 . WD classification was supported by meeting 1, 2, 3, or 4 criteria in 39%, 37%, 13%, and 4%, respectively. PD classification was supported by meeting 1 or 2 criteria in 44% and 38%, respectively. A total of 9 cases had insufficient ancillary support for final classification and underwent a re-review for consensus agreement by morphology; the final classification for these neoplasms was WD (n 5 4), PD (n 5 3), and UNC (n 5 2). Representative images of WD and PD cases with disagreement are shown in Figure 1E -G with the final classification. The ratios of WD diagnoses to PD diagnoses for the 3 reviewers were 58:14, 36:36, and 18:53. There was complete independent agreement for differentiation among all 3 reviewers in 27 of 72 cases (38%; 15 WD cases and 12 PD cases) with a j statistic of 0.16 (P 5 .008). The rates of agreement for WD and PD cases were 15 of 55 (27%) and 10 of 15 (67%), respectively. Individual reviewer diagnoses were the same as the final classification in 87%, 69%, and 49% of cases, respectively. The individual reviewer classification of WD was the same as the final classification in 93%, 62%, and 35% of cases, respectively. The individual reviewer classification of PD was the same as the final classification in 67%, 93%, and 100% of cases, respectively. Complete agreement on classification was confirmed by the final classification except in 2 cases (cases 1 and 29; Fig. 2D ,E), each with a final classification of WD but complete reviewer agreement of PD. A review of the tumor history for case 1 revealed a prior WD neoplasm with a mitotic count of 2.2 per 10 highpower fields (G2; average of 50 fields counted) that was resected 3 years before the patient underwent liver FNA (Fig. 2C) . Evidence of the underlying tumor biology for case 29 included prior FNA with a Ki-67 index of 10%, which was used as a separate case (case 25) in which the reviewers uniformly agreed that it was WD. We re-reviewed cases 25 and 29 side by side and noted the higher Ki-67 index of case 25 (29% vs 10%). Cytologically, case 25 had more ovoid, irregular, and angulated nuclei; more nuclear tangles, molding, apoptosis, and mitosis; less cytoplasm; and an absence of plasmacytoid cells (Fig. 2D, E) . The cohort included 2 additional instances of interval biopsies from the same patient, but in those other cases, all 4 FNA specimens from these patients were consistently classified as WD by all reviewers.
Two cases were not classifiable because there was no ancillary information and the reviewers could not reach a consensus on morphologic differentiation (Fig. 1H-J) . The neoplastic cells from one of these cases were small with round nuclei, small nucleoli, and variable cytoplasm arranged in tight clusters with nuclear tangles, nuclear angulation, molding, apoptoses, and mitoses (Fig. 1H,I ). The other UNC case had moderately sized plasmacytoid cells with round, smoothly contoured nuclei, but abundant cytoplasm, nuclear tangles, and mitoses made it difficult to decide on WD versus PD (Fig. 1J) .
Ten of the 16 PD PanNECs were subclassified independently with full agreement as PD-S (n 5 5) or PD-L (n 5 5; Fig. 1A-C) . After a consensus review, an additional PD-S case and an additional PD-L case were agreed upon, but the reviewers did not reach a consensus for PD-S versus PD-L for 3 PD cases (PD-UNC; Fig. 1D ). The genotypes of 2 PD-UNC cases included KRAS and RB1 mutations, among others, while lacking mutations associated with WD PanNET (DAXX, ATRX, and MEN1).
Results from testing the association of cytologic features with the presence or absence of reviewer agreement for the WD or PD status are shown in Tables 5 and 6 . Features associated with agreement for a WD status included a round nuclear shape (P 5 .03) and plasmacytoid cells (P 5 .03), whereas apoptosis (P 5 .009) and angulated nuclei (P 5 .02), when present in WD PanNETs, tended to cause disagreement. Necrosis was the only factor significantly associated with agreement for a PD status (P 5 .03).
G2 cases were included in this study to investigate whether morphologic ambiguity exists below the threshold of a 20% Ki-67 rate. None of the 19 G2 neoplasms was agreed to be PD by all 3 reviewers; however, not all G2 neoplasms were clearly WD because 58% of the G2 neoplasms (11 of 19) were called PD by at least 1 reviewer.
The medians for the Ki-67 index were 14% (range, 5%-17%) for WD G2 cases, 40% (range, 21%-89%) for WD G3 cases, and 61% (range, 22%-95%) for PD cases.
DISCUSSION
Pancreatic neuroendocrine neoplasms with Ki-67 proliferation rates exceeding 20% (WHO G3) are rare. It has recently been recognized that these high-grade neoplasms include both WD neuroendocrine tumors and PD neuroendocrine carcinomas, which have distinct biologies,
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Cancer Cytopathology The reviewers agreed that this case was poorly differentiated but could not agree on the cell type (small vs large; ThinPrep). (E) The reviewers did not agree on differentiation for this case, but the final classification was well differentiated on the basis of DAXX and MEN1 mutations. (F) The reviewers did not agree on differentiation, and RB protein expression was retained by immunohistochemistry, which was not helpful. The final classification by consensus was poorly differentiated. (G) The reviewers did not agree on this case, but the final classification was well differentiated on the basis of a prior history of a resected pancreatic neuroendocrine tumor (grade 1/2). (H-J) A consensus was not reached on differentiation for these cases, which had no supporting data for the tumor biology, so they were not classified: (H) case 5 (ThinPrep), (I) case 5 (Diff-Quik, 403), and (J) case 9 (Diff-Quik). PD-L indicates poorly differentiated large cell type; PD-S, poorly differentiated small cell type. therapeutic management, and outcomes. 2 These findings are reflected in the new 2017 WHO classification of pancreatic neuroendocrine neoplasms, which includes both WD PanNETs and PD PanNECs within the G3 category. Unlike the more commonly encountered G1 neoplasms, which usually appear to be clearly WD, the distinction between WD and PD high-grade neuroendocrine neoplasms can be difficult even when biopsy or resection specimens are available. In the current study, we have shown that with only cytologic specimens used to assess the morphology, the determination of differentiation in neuroendocrine neoplasms with elevated proliferative rates is quite challenging, even for experienced pancreatic cytopathologists. Reviewers were provided with conventional descriptions of the entities only; a training set of neoplasms . This rate exceeds the 33% agreement rate achieved by gastrointestinal pathologists in a similarly designed study focused on the histologic assessment of high-grade NEN neuroendocrine neoplasms differentiation, although that study included only G3 neoplasms. 8 In the current study, the agreement rate was higher for PD cases than WD cases (67% vs 27%), and this suggests that WD PanNETs in the G2/G3 category can be more ambiguous than PD PanNECs. We note that 58% of G2 neoplasms were called PD by at least 1 of the 3 reviewers (not consistently the same reviewer), and this suggests that morphologic ambiguity in WD PanNETs can be present even in G2 cases. The ratio of WD diagnoses to PD diagnoses for each reviewer indicated that they were clearly using different thresholds to distinguish WD cases from PD cases. Notably, 1 reviewer's diagnoses agreed with the final classification in 87% of the cases, and this raises the possibility that morphologic differentiation can be assigned if we do more work to understand the morphologic differences between WD G2 and WD G3 neoplasms. Reviewers agreed on a WD status in cases with the conventional low-grade features of a round nuclear shape and plasmacytoid cells. In contrast, WD cases that showed apoptosis and angulated nuclei tended to result in disagreement. Necrosis was the only factor significantly associated with agreement on poor differentiation. Although a third of the cases (24 of 72) were advanced disease at the initial biopsy and without treatment, approximately half of the cases that were included in Pancreatic Neuroendocrine Neoplasms/Sigel et al
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this study represented FNA biopsies of progressed disease, and this has implications for our results. Management for these rare neoplasms is heterogeneous and ranges from observation to alkylating agents and/or platinum-based chemotherapy; therefore, many neoplasms could have seen treatment possibly influencing their morphology. The reviewers were not informed whether a specimen was from the initial diagnosis or progression. Because current concepts of neuroendocrine neoplasm biology do not support the transformation of a WD PanNET into a PD PanNEC, in practice, knowledge of a prior WD Pan-NET diagnosis can inform the assessment of a presumed metastasis and should help to avoid the misclassification of a WD G3 PanNET with worrisome morphologic features as PD PanNEC. 4, 8 Moreover, it may be somewhat reassuring to note that advanced and progressive WD PanNETs may be much less frequently encountered outside institutions that routinely resample progressive or recurrent disease. Nevertheless, the phenomenon of WD PanNETs with grade transformation from G1/G2 to G3 may be underrecognized. Before this study, aside from Ki-67 staining, we had limited experience with applying ancillary immunohistochemical studies to cytology for this differential diagnosis. Ki-67 staining certainly can be helpful with a morphologically ambiguous G2 neoplasm when the proliferation rate is 20%. However, Ki-67 in most cases cannot be used as the sole support to assign differentiation in G3 neoplasms, with the caveat that proliferation rates greater than 90% are more likely to occur in PD neoplasms. We found that Rb IHC on cell blocks was challenging to interpret because hepatocyte nuclei were often the only background cells to use as potential positive internal controls, but often they showed poor nuclear staining in comparison with other nuclei (eg, lymphocytes) during antibody optimization. We also noted that retained RB staining could not be interpreted as support for WD PanNETs because it is an inconsistent abnormality in PD PanNECs, particularly in the large cell variant, which is more common than small cell carcinoma in pancreatic primaries. 4 We did not perform DAXX and ATRX IHC on cytology specimens because we were unsuccessful at optimizing these antibodies on our cell block material, which was initially fixed in ethanol. A drawback of this study is the limited ancillary support for the true differentiation status in the PD PanNECs, but final classification for the ambiguous WD PanNETs was robust because only 1 (2%) was classified as such solely by reviewer agreement without other evidence supporting a WD status.
In summary, the distinction between WD and PD pancreatic neuroendocrine neoplasms is clinically relevant for therapeutic management, and it is crucial for the diagnosis to be accurate. In this study, we show that experienced cytopathologists show disagreement on the differentiation of these neoplasms in a cohort enriched for patients with advanced disease. Our results suggest a need for further comparison of well-characterized G2 and G3 neuroendocrine neoplasms to enhance our morphologic diagnosis.
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